🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07490925
Recruiting Not applicable

Transpulmonary Pressure-guided Mechanical Ventilation Strategy in Right Ventricular Protection in Patients With ARDS

NCT07490925 · tracked via the Priya Life Science China tracker
Sponsor
Beijing Chao Yang Hospital
Phase
Not applicable
Started
2026-03-23
Last updated
2026-09-14

Condition(s) studied

ARDS (Moderate or Severe)

Investigational drug(s) / intervention(s)

Transpulmonary pressure guided mechanical ventilation strategy

Transpulmonary pressure guided mechanical ventilation strategy: Tidal volume is adjusted to achieve a target tidal volume of 6 mL/kg predicted body weight (PBW) while controlling end-inspiratory transpulmonary pressure ≤ 20 cmH₂O. PEEP is adjusted to maintain end-expiratory transpulmonary pressure between 0 and 2 cmH₂O. In control group, PEEP was titrated using the low PEEP:FiO₂ table method.

Study summary

To verify whether the transpulmonary pressure-guided mechanical ventilation strategy can reduce right ventricular involvement, especially the incidence of acute cor pulmonale (ACP), in patients with moderate to severe ARDS induced by pneumonia compared with the currently widely used right ventricular protective mechanical ventilation strategy.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: 1. Age ≥ 18 years old 2. ARDS caused by pneumonia (New Global Definition of ARDS) 3. PaO2/FiO2≤200mmHg 4. Received invasive mechanical ventilation 5. Sign the informed consent form Exclusion Criteria: 1. Invasive mechanical ventilation duration \> 48 hours 2. History of pulmonary hypertension caused by various reasons 3. Severe arrhythmia 4. BMI\>30kg/m2 5. Contraindications to inserting an esophageal catheter (including recent esophageal injury or surgery, severe coagulopathy (platelets \< 5×10⁹/L or INR \> 4) 6. Pregnant and lactating women 7. Lung transplant recipient 8. High-risk factors for increased intracranial pressure (including intracranial hemorrhage, cerebral contusion, cerebral edema, intracranial space-occupying lesions, etc.) 9. Active air leakage in the lungs (pneumothorax, mediastinal emphysema, bronchopleural fistula, air leakage from closed thoracic drainage tubes, etc.) 10. Neuromuscular disease 11. Already received salvage measures (iNO, ECMO, prone position, high-frequency oscillatory ventilation) 12. Severe liver failure 13. Participated in other ARDS-related studies within 30 days

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Beijing Chao-Yang Hospital Beijing China Recruiting

More Beijing Chao Yang Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07490925 on ClinicalTrials.gov ↗ ← All trials in China